# Oriella Ltd.

> Oriella Ltd. is a VC fund backing Biotechnology, Pharmaceutical and Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Oct 2025
- Lead investor: 0%
- Last updated: Aug 2026

Oriella Ltd. is a prominent private equity and technology investor, with an expanding focus on life sciences.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Pharmaceutical | 2 | 40% |
| Medical | 1 | 20% |
| Agriculture | 1 | 20% |
| Health Care | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series C | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Omnix Medical | Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technologywill tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide. | $25M | Series C | Oct 15, 2025 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $22M | Series B | Oct 15, 2025 |  |
| TripleW Group NV | TripleW developed and commercializes an industrial process for the production of lactic acid and Poly Lactic Acid (PLA) bioplastic from organic waste.TripleW R&D developed a simple and profitable proprietary bioprocess that converts renewable carbon from waste and turns it into lactic acid, used in everyday products, including homecare,cosmetics, and production of bioplastic for food packaging. A new era for our environment with goods made from renewable carbon-based lactic acid, preventing the release of greenhouse gases. | $16.5M | Series B | Mar 01, 2023 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M | Venture - Series Unknown | Jun 16, 2021 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $18M | Venture - Series Unknown | Feb 25, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Flerie Invest](https://shizune.co/investors/profile/flerie-invest) — VC Fund, 3 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 2 deals together
- [Cancer Focus Fund](https://shizune.co/investors/profile/cancer-focus-fund) — VC Fund, 2 deals together
- [HBL Hadasit Bio Holdings](https://shizune.co/investors/profile/hbl-hadasit-bio-holdings) — VC Fund, 2 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 2 deals together
- [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Oriella Ltd. invest in?

Oriella Ltd. invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Oriella Ltd. last invest?

The most recent investment recorded for Oriella Ltd. closed in Oct 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co